TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02008071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily step goal financial incentive
Description: Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
Study: NCT01424462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Single dose treatment IR formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B
Description: Low Extended release single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C
Description: Medium extended release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D
Description: High extended release rate single dose
Study: NCT03197025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E6 T Cell Receptor (TCR)
Description: On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E6 T Cell Receptor (TCR)
Description: On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
Study: NCT02643628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling followed by Bellafill treatment
Study: NCT01617499

Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
Study: NCT03959852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1 mg/kg of Fentanyl IV administered over at least 1 minute

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fentanyl and Ketamine
Description: Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
Study: NCT00227123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine, risperidone
Description: Flexible dose titrations to 'treat-to-symptoms'
Study: NCT04430803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water
Description: A tablet that produces hydrogen dissolved in a glass of water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Water
Description: A glass of tap water
Study: NCT03297476

Intervention type: DIAGNOSTIC_TEST
Intervention: High-risk subtype detection panels
Description: The designed detection technology were used to identify the high-risk patients cohort.

Intervention type: DIAGNOSTIC_TEST
Intervention: High-risk subtype detection panels
Description: The designed detection technology were used to identify the high-risk patients cohort.
Study: NCT02839785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
Study: NCT02880839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partial cervical lamina excision group
Description: Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline-dredge discharge group
Description: Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital navigation group
Description: Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
Study: NCT00718471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: ENOXAPARIN IV 0.5 mg.kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFH (unfractionated heparin)
Description: UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
Study: NCT04041830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit 1
Description: the participants will fill in the LFPQ questionnaire before and after a lunch test meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit 1
Description: the participants will fill in the LFPQ questionnaire before and after a lunch test meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit 2
Description: this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
Study: NCT03577314

Intervention type: OTHER
Intervention: miscarriage
Description: (ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).

Intervention type: OTHER
Intervention: miscarriage
Description: (ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
Study: NCT02318654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Pack
Description: Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical EMLA cream
Description: Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
Study: NCT03051347

Intervention type: OTHER
Group type: OTHER
Intervention: Itch Questionnaire and Interview

Intervention type: OTHER
Group type: OTHER
Intervention: Stigma Questionnaire and Interview

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Interview and PROMIS Itch Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Interview and PROMIS Itch Questionnaire
Study: NCT04122625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered as IV infusion.
Study: NCT03425994

Intervention type: DRUG
Intervention: Elvitegravir/Cobicistat/Emtricitabine
Description: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
Study: NCT01684124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative O2 therapy
Description: target lower O2 saturation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard care
Study: NCT03852498

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Lenti-D
Description: Participants received a single IV infusion of Lenti-D Drug Product.
Study: NCT03402425

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FET PET
Description: Patient are investigated with an 18F-FET PET
Study: NCT06012526

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Polysomnography is done for patients to find any sleep disordered breathing

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Polysomnography is done for patients to find any sleep disordered breathing
Study: NCT00415324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative study
Study: NCT03514056

Intervention type: DIAGNOSTIC_TEST
Intervention: group 1:Patients diagnosed with Behcet disease
Description: Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease

Intervention type: DIAGNOSTIC_TEST
Intervention: group 2: Patient diagnosed with fibromyalgia without Behcet disease
Description: Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
Study: NCT03637309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BeReady2Smile Video and App
Description: BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
Study: NCT03072823

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 Polyunsaturated fatty acid
Description: 2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: olive oil ethyl esters
Study: NCT04041830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit 2
Description: this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
Study: NCT00786643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Interferon-1b (IFN-γ)
Description: Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Interferon-1b (IFN-γ)
Description: Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
Study: NCT02552459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil 150μg， intravenous administration during post-operative 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: sufentanil 150μg， intravenous administration during post-operative 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil 150μg， intravenous administration during post-operative 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: sufentanil 150μg， intravenous administration during post-operative 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1
Description: dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 2
Description: dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 3
Description: dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
Study: NCT01807182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Tumor Infiltrating Lymphocytes
Description: Undergo TIL infusion
Study: NCT01991847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
Study: NCT00791375

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity intervention
Description: Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
Study: NCT02686099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SternaLock 360
Description: Sternal closure with SternaLock 360

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wire Cerclage
Description: Sternal closure with standard wire cerclage
Study: NCT00609401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib)
Description: 400 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib)
Description: 400 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 3 MU per 5 day/week for 2 weeks every 4
Study: NCT00926081

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise training
Description: A standardized supervised exercise training program
Study: NCT02999243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Description: The intervention group will be offered HIV self-testing kits for testing HIV status

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Harm reduction education
Description: Both arms will receive harm reduction education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harm reduction education
Description: Both arms will receive harm reduction education
Study: NCT02846493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bromocriptine
Description: Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
Study: NCT01874509

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Check Your Drinking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Help Centre
Study: NCT04543383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-Factor Prothrombin Complex Concentrate (4F-PCC)
Description: 4F-PCC will be administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Factor VIIa (rFVIIa)
Description: rFVIIa will be administered intravenously.
Study: NCT05302947

Intervention type: DRUG
Intervention: Baricitinib Oral Tablet
Description: Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition

Intervention type: DRUG
Intervention: Tocilizumab Injection
Description: Tocilizumab was administered by a single intravenous dose of 400 mg
Study: NCT04543383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Factor VIIa (rFVIIa)
Description: rFVIIa will be administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching to 4F-PCC
Description: Placebo matching to 4F-PCC will be administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching to rFVIIa
Description: Placebo matching to rFVIIa will be administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching to rFVIIa
Description: Placebo matching to rFVIIa will be administered intravenously.
Study: NCT03645148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01
Description: Neoantigen peptides

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: immune adjuvant
Study: NCT02608736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
Study: NCT03178045

Intervention type: OTHER
Intervention: Team Monitoring
Description: In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.

Intervention type: OTHER
Intervention: Enhanced Feedback
Description: In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.